Department of Medical-Surgery Sciences and Translational Medicine, Sapienza University, Sant Andrea Hospital, Rome, Italy.
Clin Chem Lab Med. 2012 Dec;50(12):2093-105. doi: 10.1515/cclm-2012-0289.
The quantitative and qualitative estimation of total body fluid content has proven to be crucial for both diagnosis and prognosis assessment in patients with heart failure. The aim of this review is to summarize the current techniques for assessing body hydration status as well as the principal biomarkers associated with acute heart failure (AHF). Although clinical history, physical examination and classical imaging techniques(e.g., standard radiography and echocardiography)still represent the cornerstones, novel and promising tools,such as biomarkers and bio-electrical impedance are achieving an emerging role in clinical practice for the assessment of total body fluid content. In the acute setting, the leading advantages of these innovative methods over device are represented by the much lower invasiveness and the reasonable costs, coupled with an easier and faster application. This article is mainly focused on AHF patients, not only because the overall prevalence of this disease is dramatically increasing worldwide, but also because it is well-known that their fluid overload has a remarkable diagnostic and prognostic significance. It is thereby conceivable that the bio-electrical vector analysis (BIVA) coupled with laboratory biomarkers might achieve much success in AHF patient management in the future, especially for assisting diagnosis, risk stratification,and therapeutic decision-making.
定量和定性评估总体体液含量已被证明对心力衰竭患者的诊断和预后评估至关重要。本综述的目的是总结目前评估身体水合状态的技术以及与急性心力衰竭(AHF)相关的主要生物标志物。尽管临床病史、体格检查和经典影像学技术(例如标准放射学和超声心动图)仍然是基石,但新型有前途的工具,如生物标志物和生物电阻抗,在评估总体体液含量方面在临床实践中发挥着越来越重要的作用。在急性情况下,这些创新方法相对于设备的主要优势在于侵入性更低、成本合理,并且应用更简单、更快速。本文主要关注 AHF 患者,不仅因为这种疾病的总体患病率在全球范围内急剧增加,还因为众所周知,他们的液体超负荷具有显著的诊断和预后意义。因此,可以想象,生物电阻抗向量分析(BIVA)结合实验室生物标志物可能在未来的 AHF 患者管理中取得巨大成功,特别是在辅助诊断、风险分层和治疗决策方面。